Figure 4
From: Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Amyloid imaging of Alzheimer’s disease and frontotemporal dementia. Typical amyloid positron emission tomography (Pittsburgh Compound B-PET), fluorodeoxyglucose (FDG)-PET and magnetic resonance imaging (MRI) images seen in a cognitively normal individual (CN), an Alzheimer’s disease (AD) patient and a frontotemporal dementia (FTD) patient. The CN individual shows no evidence of amyloid deposition, normal metabolic uptake and normal structural MRI scan. The AD patient shows significant amyloid uptake throughout the brain, significant low parietal lobe FDG uptake and significant ventricular expansion on the MRI scan. The FTD patient shows no significant amyloid deposition, significant frontal and temporal lobe deficits and atrophy, which are both highly asymmetric.